<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0020">
 <label>20</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Hollak</surname>
    <given-names>CEM</given-names>
   </name>, 
   <name name-style="western">
    <surname>Hughes</surname>
    <given-names>D</given-names>
   </name>, 
   <name name-style="western">
    <surname>van Schaik</surname>
    <given-names>IN</given-names>
   </name>, 
   <etal>et al.</etal>
  </person-group>
  <article-title>Miglustat (Zavesca®) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme</article-title>. 
  <source>Pharmacoepidemiol Drug Saf</source>
  <year>2009</year>;
  <volume>18</volume>:
  <fpage>770</fpage>–
  <lpage>7</lpage>.
  <pub-id pub-id-type="pmid">19507165</pub-id>
 </mixed-citation>
</ref>
